Navigation Links
FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data
Date:3/17/2008

Eventually, these problems may cause life-threatening complications, such as overwhelming infections and fatal bleeding. More information about CLL can be accessed at the website for the Lymphoma Research Foundation at: http://www.lymphoma.org.

About Genasense

Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing Tesetaxel(R), a novel, orally absorbed, semi- synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the United States
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Extends Review of Genasense(R) NDA Appeal in Chronic Lymphocytic Leukemia
2. FDA to Extend Review of Data Quality Submission for Genasense(R) in Melanoma
3. Genasense(R) Data in Patients with Advanced Melanoma to be Featured at 4th International Melanoma Congress
4. Genasense(R) Can be Administered by Brief High-Dose IV Infusion
5. Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
6. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
7. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
8. FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent
9. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
10. DuraHeart(TM) LVAS Receives Conditional Approval for US Pivotal Trial
11. Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ... stock of Solta Medical, Inc. (NASDAQ: SLTM ...
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... results for the fourth quarter of 2013 on Monday, February ... for release after the close of trading. ... conference call to discuss the operating highlights and financial results ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... (NYSE: DHR ) announced today that Henk ... and Amir Aghdaei and Henrik Roos have each been ... In his new role, Henk van Duijnhoven will ... Group and Sybron Dental Specialties.  Danaher,s Dental segment generated ...
... ALISO VIEJO, Calif., April 5, 2011 Avanir Pharmaceuticals, Inc. ... will present an overview of the company at the Future Leaders ... Location: Millennium Broadway Hotel & Conference Center, New York, ... Presentation time: 2:00pm ET A live ...
Cached Medicine Technology:Danaher Announces Executive Appointments 2
(Date:4/22/2014)... patients diagnosed with non-small cell lung cancer are 70 ... percentage, these elderly patients are not well represented in ... made it difficult to reach evidence based clinical recommendations. ... Task Force and Lung Cancer Group along with the ... opinion on managing treatment for elderly patients with non-small ...
(Date:4/22/2014)... trauma, illness, alcohol or other drug abuse, these stressors ... that can go awry and activate conditions such as ... , Until now, it has been unclear how much ... brain. Past studies have shown that when an expectant ... she experiences some trauma or illness, her baby may ...
(Date:4/22/2014)... intervention researchers have been informed that the National Institute ... Institutes of Health, will award an $8 million grant ... an experimental drug for stroke. , The drug, ... plasminogen activator, or rtPA the "clot-busting" drug currently ... laboratory rodent studies, 3K3A-APC, used in combination with rtPA, ...
(Date:4/22/2014)... a clinical trial led by Dana-Farber Cancer Institute ... approved a molecularly targeted drug as second-line treatment ... standard chemotherapy has failed. , The FDA approval ... manufacturer, Lilly Oncology, of Indianapolis. A monoclonal antibody ... sold under the name Cyramza, and is the ...
(Date:4/22/2014)... the University of Calgary,s Hotchkiss Brain Institute (HBI) uncovers ... as a means to restore connections after injury. Dr. ... molecule that directly regulates nerve cell growth in the ... prestigious journal Nature Communications , with lead authors ... made the surprising discovery that a protein called Retinoblastoma ...
Breaking Medicine News(10 mins):Health News:EORTC and SIOG update expert opinion on management of elderly patients with NSCLC 2Health News:Life stressors trigger neurological disorders, researchers find 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 3Health News:FDA approves first targeted drug for advanced stomach cancer 2Health News:Scientists discover a new way to enhance nerve growth following injury 2
... , ... ... ... ...
... ... ... ... ...
... sheds light on brain mechanism related to processing images , ... recognizing faces may be relieved to know that the problem ... could be in their genes, new research suggests. , The ... genes) and 125 non-identical, same-sex twins (who share 50 percent ...
... C. Bray of the University of Calgary was recently ... for Sports Medicine,s (AOSSM) $250,000 Ligament and Tendon Repair ... Ligament and Tendon Healing: Role of Neuropeptides." ... of Calgary, and Per Renstrom and Paul Ackermann, both ...
... mechanisms of transport have important applicationstransport of nutrients ... aeration of agricultural soils, performance of chemical reactors, ... and the design of clay membranes for retaining ... has important roles in biology, physics, and chemistry, ...
... ... depression and stress with amazing technology; free assessments offered in March. , ... Arlington, TX (Vocus) February 24, 2010 -- The ... trigger anxiety, loneliness, depression and even thoughts of suicide. At New Life Brain Center™, ...
Cached Medicine News:Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 2Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 3Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 4Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 5Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 6Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 7Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 8Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 9Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 10Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 11Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 12Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 13Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 14Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 15Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 16Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 17Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 18Health News:Soyfoods Aid Those With Lactose Intolerance 2Health News:Soyfoods Aid Those With Lactose Intolerance 3Health News:Soyfoods Aid Those With Lactose Intolerance 4Health News:Soyfoods Aid Those With Lactose Intolerance 5Health News:Trouble Recognizing Faces Could Be Genetic 2Health News:$250,000 grant awarded for groundbreaking ligament and tendon repair research 2Health News:Where does the fluid go? 2Health News:Brain Balancing Gives Hope for Sufferers of Depression, Stress, and Insomnia at New Life Brain Center, 2Health News:Brain Balancing Gives Hope for Sufferers of Depression, Stress, and Insomnia at New Life Brain Center, 3
Complete Cataract Competence , OPMI VISU 140 is compact, good and economical. It's everything a cataract specialist needs today....
BD Vacutainer® Specialty Tubes - Acid Citrate Dextrose (ACD)...
... BD Vacutainer® SST™ Tubes ... a polymer gel for ... used for serum determinations ... provide an efficient means ...
MONOJECT Red/Yellow Mottled Stopper...
Medicine Products: